Date Initiated: 10/17/2017
The Class includes any person or entity in the United States who paid or provided reimbursement for some or all of the purchase price of branded or authorized generic EpiPens for the purpose of consumption, and not resale, by themselves, their family, insureds, plan participants, employees, or beneficiaries, at any point between Aug. 24, 2011, and Nov. 1, 2020, and did not exclude themselves from the Class during the initial notice period.
Date Initiated: 07/23/2021
The Class includes any person or entity in the United States who paid or provided reimbursement for some or all of the purchase price of branded or authorized generic EpiPens for the purpose of consumption, and not resale, by themselves, their family, insureds, plan participants, employees, or beneficiaries, at any point between Aug. 24, 2011, and Nov. 1, 2020, and did not exclude themselves from the Class during the initial notice period.
In re: EpiPen Marketing, Sales Practices, and Antitrust Litigation, Civil Action No. 2:17-md-02785-DDC-TJJ (MDL No: 2785), in the U.S. District Court District of Kansas
Date Initiated: 10/17/2017
Consumers filed their EpiPen class action lawsuit in 2017, claiming Pfizer other defendants plotted to maintain EpiPen’s monopoly by issuing large rebates to insurers and Medicaid plans that refused to cover competing medications. The class action was filed after the price of EpiPens rose from $100 to $600 in under 10 years.
The Class includes any person or entity in the United States who paid or provided reimbursement for some or all of the purchase price of branded or authorized generic EpiPens for the purpose of consumption, and not resale, by themselves, their family, insureds, plan participants, employees, or beneficiaries, at any point between Aug. 24, 2011, and Nov. 1, 2020, and did not exclude themselves from the Class during the initial notice period.
Date Initiated: 07/23/2021
The Court granted preliminary approval to this settlement July 23, 2021.
The current settlement does not resolve claims against other defendants in the class action lawsuit: Mylan N.V., Mylan Specialty L.P., Mylan Pharmaceuticals Inc., Viatris Inc., or Heather Bresch (the “Mylan defendants”). A trial over those claims is scheduled to begin Jan. 24, 2022.
The settlement funds are divided into two pools: one for individual consumers and one for third-party payors.
Eighty percent will be allocated to the third-party payor Class Member pool, while the remaining 20 percent will be allocated to the individual consumer pool.
Within each pool, Class Members’ individual recovery will be a portion of that pool to be determined by the Class Member’s allowed claim compared to the total allowed claims of all Class Members in the same pool who also submit valid and timely claims.
Class Members who choose not to take any action give up their right to ever be part of any other lawsuit against the Pfizer defendants about the legal claims resolved by this settlement.
The deadline to object to the settlement has passed.
The claim deadline is Nov. 12, 2021.
The claim deadline was Nov. 12, 2021.
